Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781543 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL6625172 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL22994670 | 0.88 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL13779901 | 0.87 | NR1H2 (0.42) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL29097169 | 0.84 | NR1H2 (0.51) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL19617652 | 0.84 | NR1H2 (0.51) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL31740849 | 0.84 | NR1H2 (0.51) | HSD17B10SMN1; SMN2NR1H2NR1H3NPC1 | |
| SCHEMBL18027 | 0.84 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NR1H2USP2LMNA | |
| SCHEMBL2364954 | 0.84 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NR1H2USP2LMNA | |
| SCHEMBL22227 | 0.84 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NR1H2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20220380347-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-01 | — | — | US | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021037205-A1 | COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOF | 苏州瑞博生物技术股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2010075356-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-01 | — | — | WO | disclosed |
| US-6458790-B2 | DIETETICS; ANTIDABETIC AGENTS; SEXUAL DISRDERS | MERCK & CO., INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MERCK SHARP & DOHME CORP. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HSD17B10 2485/4885SMN1; SMN2 1498/4885NR1H2 2419/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885NR1H2 3775/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885NR1H2 3775/4885 |
| US-20220380347-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | HSD17B10 1711/4885SMN1; SMN2 4032/4885NR1H2 4588/4885 |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MC4R, MC5R, MC3R | HSD17B10 3022/4885SMN1; SMN2 1936/4885NR1H2 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.